HK inno.N
195940, KOSDAQ, Healthcare
- Prev. close
- ₩39,151
- Volume
- 56.1K
- Market cap
- ₩1.1T
- Near 52-week low
- -33% from high
- Low-volatility blue chip
Stock and sector context
Healthcareinflow- Sector comparison
- HK inno.N changed -0.13%. The 13 covered Healthcare stocks in Korean averaged +0.59%, with estimated sector flow of inflow.
- Variables to watch
- Drug approvals and trial resultsDrug pricing policyUS interest ratesUSD/KRW
- Risks to check
- -33% below the high, the downtrend may continue
- Clinical trial failure
- Drug pricing pressure
This compares price changes among covered stocks in the same market. It does not establish why prices moved. Variables and risks are sector reference lists.
Why a candidate
Exp 48/100The 0–100 score combines the 52-week range, valuation metrics, price changes and volume. It is not a probability of rising or a forecast return.
Today's read
HK inno.N scores 48 out of 100 on today's InverseOne expectation ranking, 41 of 60 in the Korean large-cap universe. There is 50% of room left to its 52-week high. Today's move of -0.13% came with money flowing out; the broader Healthcare sector flow is worth checking. Scores are estimates built from price and volume, a starting point for research rather than a trading signal.
Data basis: 2026-09-17 close, 09-19 00:18 KST updated, For reference only, not advice
Same-sector stocks, Healthcare
Lending balance
Unwinding1,584,551 sh
KRW 0.06T
New 45,105 sh, Returned 63,296 sh
Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.
As of 2026-09-17, FSC stock lending data
Talk about this stock
Today's talking points
- It sits low in its 52-week range (18).
- Borrowed shares are coming back. The lending balance is shrinking.
- It is 50% below its 52-week high.
Three months out, which way do you see it?
Nobody has answered yet. Sign in to be the first.
These are answers picked by members, not investment advice.
These figures are reference estimates built from price and volume: a starting point for narrowing down ideas, not a buy or sell signal.